

Table 2.3 (Continued) Potential U.S. Biosimilar Candidates through 2024

<b>Brand</b>	<b>Generic Name</b>	<b>Therapeutic Category</b>	<b>Worldwide Annual Sales (2015) (\$millions)</b>	<b>Patent Expiry</b>
Rituxan	Rituximab	Oncology and immunomodulators	7,153	Dec 2018
Xolair	Omalizumab	Respiratory	1,222	Dec 2018
	Omalizumab	Respiratory	803	Dec 2018
Forteo	Teriparatide recombinant human	Musculoskeletal	1,305	Dec 2018
Pegasys	Peginterferon alfa-2a	Oncology and immunomodulators	645	Dec 2018
Prochymal	Remestemcel-L	Oncology and immunomodulators	267	Dec 2018
Elonva	Corifollitropin alfa	Genitourinary	47	Dec 2018
Voraxaze	Glucarpidase	Oncology and immunomodulators	24	Jan 2019
RotaTeq	Rotavirus vaccine	Systemic antiinfectives	665	Feb 2019
Arcalyst	Riloncept	Oncology and immunomodulators	17	May 2019
Herceptin	Trastuzumab	Oncology and immunomodulators	6,517	Jun 2019
Levemir	Insulin detemir recombinant	Endocrine	2,722	Jun 2019
Avastin	Bevacizumab	Oncology and immunomodulators	6,695	Jul 2019
Elaprase	Idursulfase	Various	586	Sep 2019
Orencia	Abatacept	Musculoskeletal	995	Oct 2019
Orencia SC	Abatacept	Musculoskeletal	770	Oct 2019
Actemra	Tocilizumab	Musculoskeletal	1,217	Nov 2019
	Tocilizumab	Musculoskeletal	225	Nov 2019
Aldurazyme	Laronidase	Various	206	Nov 2019
Advate	Factor VIII (procoagulant)	Blood	2,085	Dec 2019
Zevalin	Ibritumomab tiuxetan	Oncology and immunomodulators	23	Dec 2019
Vectibix	Panitumumab	Oncology and immunomodulators	589	Apr 2020
Lucentis	Ranibizumab	Sensory organs	1,770	Jun 2020
Afrezza	Insulin (human)	Endocrine	33	Jun 2020
Botox	OnabotulinumtoxinA	Musculoskeletal	2,675	Jul 2020
Tysabri	Natalizumab	Central nervous system	2,094	Dec 2020
Recombivax HB	Hepatitis B vaccine	Systemic antiinfectives	184	Dec 2020
Cervarix	Human papillomavirus vaccine	Systemic antiinfectives	177	Dec 2020

*(Continued)*